{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer&page=58",
    "query": {
      "condition": "Ovarian Cancer",
      "page": 58
    },
    "page_size": 10
  },
  "pagination": {
    "page": 58,
    "page_size": 10,
    "total_count": 2469,
    "total_pages": 247,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer&page=59&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer&page=57&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-05T07:40:11.040Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04602117",
      "title": "ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "HER2 Low",
        "SYD-985",
        "SYD985",
        "Vic-trastuzumab Duocarmazine",
        "Metastatic Cancer",
        "Metastatic Breast Cancer",
        "Metastatic Gastrointestinal Carcinoid Tumor",
        "Metastatic",
        "HER2 Low Breast Cancer",
        "GastroEsophageal Cancer",
        "Gastroesophageal Adenocarcinoma",
        "Endometrium Tumor",
        "Ovarian Cancer",
        "Ovarian Carcinoma",
        "HER2-positive Gastric Cancer",
        "HER2-positive Metastatic Breast Cancer",
        "HER2 Mutation-Related Tumors",
        "HER-2 Protein Overexpression",
        "HER2 Low HR Positive",
        "HR Positive",
        "Hormone Receptor-positive Breast Cancer",
        "Estrogen Receptor Positive Tumor",
        "Progesterone Receptor-positive Breast Cancer",
        "Triple Negative Breast Cancer",
        "Hormone Receptor Negative Breast Carcinoma",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Vic-trastuzumab duocarmazine (SYD985) + paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QuantumLeap Healthcare Collaborative",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-07-28",
      "completion_date": "2021-11-17",
      "has_results": false,
      "last_update_posted_date": "2023-11-18",
      "last_synced_at": "2026-11-05T07:40:11.040Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04602117"
    },
    {
      "nct_id": "NCT01790789",
      "title": "Stress Reduction in Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ovarian, Fallopian, and Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "Daily stress reduction program",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Attention control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 41,
      "start_date": "2013-02",
      "completion_date": "2016-12-06",
      "has_results": false,
      "last_update_posted_date": "2019-11-19",
      "last_synced_at": "2026-11-05T07:40:11.040Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01790789"
    },
    {
      "nct_id": "NCT02788708",
      "title": "Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Fallopian Tube Carcinoma",
        "Recurrent Ovarian Cancer",
        "Primary Peritoneal Carcinoma",
        "Recurrent Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "Lenvatinib Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Floor Backes",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 26,
      "start_date": "2016-05-27",
      "completion_date": "2022-03-31",
      "has_results": false,
      "last_update_posted_date": "2022-09-19",
      "last_synced_at": "2026-11-05T07:40:11.040Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02788708"
    },
    {
      "nct_id": "NCT05743517",
      "title": "Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ovary Cancer",
        "Endometrial Cancer",
        "Uterine Cancer",
        "Cervical Cancer",
        "Cervix Cancer",
        "Vulvar Cancer",
        "Vaginal Cancer"
      ],
      "interventions": [
        {
          "name": "Fit4Treatment",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "60 Years and older · Female only"
      },
      "enrollment_count": 192,
      "start_date": "2023-09-15",
      "completion_date": "2029-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-11-05T07:40:11.040Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05743517"
    },
    {
      "nct_id": "NCT05032040",
      "title": "A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Clear Cell Carcinoma",
        "Endometrial Cancer",
        "Cervical Carcinoma",
        "Metastatic Castration-Resistant Prostate Cancer (mCRPC)"
      ],
      "interventions": [
        {
          "name": "vudalimab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Xencor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 170,
      "start_date": "2022-07-21",
      "completion_date": "2025-12-30",
      "has_results": false,
      "last_update_posted_date": "2025-02-07",
      "last_synced_at": "2026-11-05T07:40:11.040Z",
      "location_count": 17,
      "location_summary": "Prescott, Arizona • La Jolla, California • Los Angeles, California + 12 more",
      "locations": [
        {
          "city": "Prescott",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05032040"
    },
    {
      "nct_id": "NCT01432015",
      "title": "Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Uterine Cancer"
      ],
      "interventions": [
        {
          "name": "fosaprepitant",
          "type": "DRUG"
        },
        {
          "name": "aprepitant",
          "type": "DRUG"
        },
        {
          "name": "Oral Placebo",
          "type": "OTHER"
        },
        {
          "name": "IV placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Gynecologic Oncology Associates",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2011-09",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2017-03-28",
      "last_synced_at": "2026-11-05T07:40:11.040Z",
      "location_count": 1,
      "location_summary": "Newport Beach, California",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01432015"
    },
    {
      "nct_id": "NCT00268918",
      "title": "Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Endometrial Cancer",
        "Cervical Cancer",
        "Fallopian Tube Cancer",
        "Peritoneal Cancer",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "PTK787",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 24,
      "start_date": "2005-09",
      "completion_date": "2011-01",
      "has_results": false,
      "last_update_posted_date": "2018-07-27",
      "last_synced_at": "2026-11-05T07:40:11.040Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00268918"
    },
    {
      "nct_id": "NCT01579812",
      "title": "Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian, Fallopian Tube, and Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "79 Years",
        "sex": "FEMALE",
        "summary": "19 Years to 79 Years · Female only"
      },
      "enrollment_count": 90,
      "start_date": "2011-10",
      "completion_date": "2017-07",
      "has_results": true,
      "last_update_posted_date": "2018-05-25",
      "last_synced_at": "2026-11-05T07:40:11.040Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01579812"
    },
    {
      "nct_id": "NCT05123807",
      "title": "Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Cytoreductive surgery",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2022-01-07",
      "completion_date": "2027-02-02",
      "has_results": false,
      "last_update_posted_date": "2026-10-07",
      "last_synced_at": "2026-11-05T07:40:11.040Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05123807"
    },
    {
      "nct_id": "NCT02433626",
      "title": "Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Endometrial Cancer",
        "Cervical Cancer",
        "Peritoneal Cancer",
        "Head and Neck Cancer",
        "HNSCC",
        "Colorectal Cancer",
        "Lung Cancer",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "COTI2",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Critical Outcome Technologies Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2015-12",
      "completion_date": "2020-06",
      "has_results": false,
      "last_update_posted_date": "2019-02-01",
      "last_synced_at": "2026-11-05T07:40:11.040Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02433626"
    }
  ]
}